The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of trial-eligibility as factor for clinical outcome of patients with renal cell carcinoma treated with first-line pazopanib: Subgroup analysis from the prospective, non-interventional study PAZOREAL.
 
Martin Schostak
Honoraria - AstraZeneca/MedImmune; Bayer; Janssen Oncology; Merck; Pfizer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb/Pfizer; EDAP TMS; Ipsen; Janssen Oncology; MSD Oncology; Sanofi
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb Foundation (Inst); Ipsen (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Bristol-Myers Squibb/Pfizer; EDAP TMS; Merck; MSD Oncology; Pfizer; Sanofi
 
Martin Boegemann
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer/Vital; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen-Cilag; Merck; MSD; Novartis; Pfizer; Roche; Sanofi/Aventis
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; ipsen; Janssen-Cilag; Merck; MSD; Novartis; Roche; Sanofi
Research Funding - IPSEN (Inst); Janssen-Cilag
Travel, Accommodations, Expenses - Amgen; Bayer; Janssen-Cilag
 
Peter J. Goebell
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche; Sanofi
 
Viktor Gruenwald
Stock and Other Ownership Interests - AstraZeneca; Bristol-Myers Squibb; Genmab; MSD; Seagen
Honoraria - Advanced Accelerator Applications/Novartis; Apogepha; AstraZeneca; Bristol-Myers Squibb; ClinSol; Eisai; EUSA Pharma; Ipsen; Janssen-Cilag; Merck Serono; MSD Oncology; Nanobiotix; Novartis; Ono Pharmaceutical; Pfizer; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Cor2Ed; Debiopharm Group; Eisai; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Onkowissen; Pfizer
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); MSD Oncology (Inst); Novartis (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Pfizer
 
Manfred Welslau
No Relationships to Disclose
 
Rainer Ehness
Employment - Novartis
Stock and Other Ownership Interests - GlaxoSmithKline; Novartis
 
Elisa Degenkolbe
Employment - Novartis
 
Stefanie Witecy
Employment - Apogepha
Stock and Other Ownership Interests - Bayer
 
Christian Doehn
Stock and Other Ownership Interests - AstraZeneca; Bayer; Bayer; Biontech; Pfizer
Honoraria - Apogepha; BMS; EUSA Pharma; Ipsen; MSD; Pfizer; Roche
Consulting or Advisory Role - Apogepha; BMS; Eisai; EUSA Pharma; Ipsen; Merck Serono; MSD; Pfizer; Roche